These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 28807001)

  • 1. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
    Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
    J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS
    Li S; Liu S; Deng J; Akbay EA; Hai J; Ambrogio C; Zhang L; Zhou F; Jenkins RW; Adeegbe DO; Gao P; Wang X; Paweletz CP; Herter-Sprie GS; Chen T; Gutiérrez-Quiceno L; Zhang Y; Merlino AA; Quinn MM; Zeng Y; Yu X; Liu Y; Fan L; Aguirre AJ; Barbie DA; Yi X; Wong KK
    Clin Cancer Res; 2018 Oct; 24(19):4854-4864. PubMed ID: 29945997
    [No Abstract]   [Full Text] [Related]  

  • 3. Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response.
    Norgard RJ; Budhani P; O'Brien SA; Xia Y; Egan JN; Flynn B; Tagore JR; Seco J; Peet GW; Mikucka A; Wasti R; Chan LC; Hinkel M; Martinez-Morilla S; Pignatelli J; Trapani F; Corse E; Feng D; Kostyrko K; Hofmann MH; Liu K; Kashyap AS
    Cancer Res Commun; 2024 Jun; 4(6):1548-1560. PubMed ID: 38727236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.
    Panagi M; Voutouri C; Mpekris F; Papageorgis P; Martin MR; Martin JD; Demetriou P; Pierides C; Polydorou C; Stylianou A; Louca M; Koumas L; Costeas P; Kataoka K; Cabral H; Stylianopoulos T
    Theranostics; 2020; 10(4):1910-1922. PubMed ID: 32042344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance.
    Rodriguez BL; Chen L; Li Y; Miao S; Peng DH; Fradette JJ; Diao L; Konen JM; Alvarez FRR; Solis LM; Yi X; Padhye A; Gibson LA; Ochieng JK; Zhou X; Wang J; Gibbons DL
    Front Immunol; 2023; 14():1161869. PubMed ID: 37449205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer.
    Wagner S; Vlachogiannis G; De Haven Brandon A; Valenti M; Box G; Jenkins L; Mancusi C; Self A; Manodoro F; Assiotis I; Robinson P; Chauhan R; Rust AG; Matthews N; Eason K; Khan K; Starling N; Cunningham D; Sadanandam A; Isacke CM; Kirkin V; Valeri N; Whittaker SR
    Oncogene; 2019 Mar; 38(10):1717-1733. PubMed ID: 30353166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cordycepin synergizes with CTLA-4 blockade to remodel the tumor microenvironment for enhanced cancer immunotherapy.
    Chen L; Zheng X; Huang H; Feng C; Wu S; Chen R; Jiang H; Yuan M; Fu Y; Ying H; Zhou J; Jiang J
    Int Immunopharmacol; 2023 Nov; 124(Pt A):110786. PubMed ID: 37611443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.
    Christmas BJ; Rafie CI; Hopkins AC; Scott BA; Ma HS; Cruz KA; Woolman S; Armstrong TD; Connolly RM; Azad NA; Jaffee EM; Roussos Torres ET
    Cancer Immunol Res; 2018 Dec; 6(12):1561-1577. PubMed ID: 30341213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.
    Jenkins KA; Park M; Pederzoli-Ribeil M; Eskiocak U; Johnson P; Guzman W; McLaughlin M; Moore-Lai D; O'Toole C; Liu Z; Nicholson B; Flesch V; Qiu H; Clackson T; O'Hagan RC; Rodeck U; Karow M; O'Neil J; Williams JC
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38164757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Combination Strategies for the A
    Voronova V; Peskov K; Kosinsky Y; Helmlinger G; Chu L; Borodovsky A; Woessner R; Sachsenmeier K; Shao W; Kumar R; Pouliot G; Merchant M; Kimko H; Mugundu G
    Front Immunol; 2021; 12():617316. PubMed ID: 33737925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition.
    Newton JM; Hanoteau A; Liu HC; Gaspero A; Parikh F; Gartrell-Corrado RD; Hart TD; Laoui D; Van Ginderachter JA; Dharmaraj N; Spanos WC; Saenger Y; Young S; Sikora AG
    J Immunother Cancer; 2019 Aug; 7(1):216. PubMed ID: 31409394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models.
    Kaistha BP; Kar G; Dannhorn A; Watkins A; Opoku-Ansah G; Ilieva K; Mullins S; Anderton J; Galvani E; Garcon F; Lapointe JM; Brown L; Hair J; Slidel T; Luheshi N; Ryan K; Hardaker E; Dovedi S; Kumar R; Wilkinson RW; Hammond SA; Eyles J
    Cancer Biol Ther; 2024 Dec; 25(1):2296048. PubMed ID: 38206570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced CTLA-4 blockade anti-tumor immunity with APG-157 combination in a murine head and neck cancer.
    Shin DS; Basak S; Veena MS; Comin-Anduix B; Bhattacharya A; Dong TS; Ko A; Han P; Jacobs J; Moatamed NA; Avila L; Pellegrini M; Wang M; Srivatsan ES
    Cancer Med; 2024 May; 13(9):e7212. PubMed ID: 38686626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition.
    Urick ME; Chung EJ; Shield WP; Gerber N; White A; Sowers A; Thetford A; Camphausen K; Mitchell J; Citrin DE
    Clin Cancer Res; 2011 Aug; 17(15):5038-47. PubMed ID: 21690569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice.
    Meyblum L; Chevaleyre C; Susini S; Jego B; Deschamps F; Kereselidze D; Bonnet B; Marabelle A; de Baere T; Lebon V; Tselikas L; Truillet C
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37949616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.
    Mukherjee D; Romano E; Walshaw R; Zeef LAH; Banyard A; Kitcatt SJ; Cheadle EJ; Tuomela K; Pendharkar S; Al-Deka A; Salerno B; Raby S; Mills IG; Honeychurch J; Illidge TM
    Oncoimmunology; 2023; 12(1):2223094. PubMed ID: 37332616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.
    Kohlmeyer JL; Lingo JJ; Kaemmer CA; Scherer A; Warrier A; Voigt E; Raygoza Garay JA; McGivney GR; Brockman QR; Tang A; Calizo A; Pollard K; Zhang X; Hirbe AC; Pratilas CA; Leidinger M; Breheny P; Chimenti MS; Sieren JC; Monga V; Tanas MR; Meyerholz DK; Darbro BW; Dodd RD; Quelle DE
    Clin Cancer Res; 2023 Sep; 29(17):3484-3497. PubMed ID: 37410426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy.
    Shen W; Li Y; Yang Z; Li W; Cao Y; Liu Y; Wang Z; Pei R; Xing C
    J Nanobiotechnology; 2024 Apr; 22(1):154. PubMed ID: 38581017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.
    Do K; Speranza G; Bishop R; Khin S; Rubinstein L; Kinders RJ; Datiles M; Eugeni M; Lam MH; Doyle LA; Doroshow JH; Kummar S
    Invest New Drugs; 2015 Jun; 33(3):720-8. PubMed ID: 25637165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen receptor blockade and radiation therapy cooperate to enhance the response of immunologically cold ER+ breast cancer to immunotherapy.
    O'Leary KA; Bates AM; Jin WJ; Burkel BM; Sriramaneni RN; Emma SE; Nystuen EJ; Sumiec EG; Ponik SM; Morris ZS; Schuler LA
    Breast Cancer Res; 2023 Jun; 25(1):68. PubMed ID: 37312163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.